News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaxart, Inc. Creates Effective Oral H7N9 Avian Influenza Vaccine in 20 Days



6/26/2013 9:43:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced successful results for its candidate H7N9 avian influenza vaccine in preclinical testing, where the Vaxart vaccine induced robust anti-hemagglutinin (anti-HA) titers.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES